

**STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 158-2 (GENERAL MEDICINES)**

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
<b>1</b>	<b>9M INDIA LIMITED</b>	Firm Remarks: All the required documents are in order and are satisfactory except Non Conviction Certificate. Hence the firm is considered for S.No. 1 to 14, 16, 17, 21, 22, 23, 24, 25, 26 products after submitting the latest Non Conviction Certificate. For products S.No. 15, 18, 19, 20 may be considered after submission of product approval.			
	<b>1</b>	<b>1188</b>	Amikacin Sulphate Injection IP 100 mg in 2 ml Ampoule	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>2</b>	<b>1736</b>	Amiodarone Hcl Injection IP 150 mg /3 ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>3</b>	<b>1693</b>	Atropine Sulphate Injection IP 0.6 mg /ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>4</b>	<b>1741</b>	Baclofen Tablet IP 10mg	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>5</b>	<b>69</b>	Betamethasone Sodium Phosphate Injection IP 4mg/ml in 1 ml amp	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>6</b>	<b>1455</b>	Betaxolol eye Drops 0.25 percentage , 5 ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>7</b>	<b>123</b>	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>8</b>	<b>221.02</b>	Dexamethasone Injection IP 8 mg / 2ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>9</b>	<b>2462</b>	Diclofenac Sodium Injection Aqueous Base 75 mg/1 ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>10</b>	<b>1215</b>	Dicyclomine Hcl Injection IP 10mg/ml in 2ml amp	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>11</b>	<b>252</b>	Enalapril Tablets 10mg	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>12</b>	<b>266</b>	Furosemide Injection , IP 10mg/1ml in 2 ml amp	Submitted, May be considered after submission of NCC certificate	May not be considered
	<b>13</b>	<b>265</b>	Furosemide Tablets IP 40mg	Submitted, May be considered after submission of NCC certificate	May not be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
	14	303	Gentamicin Eye Drops IP 0.3 Percentage w/v in 5ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	15	1836	Haloperidol Deconate Inj. 50mg	Not submitted, May be considered after submission of product approval	May not be considered
	16	745	Haloperidol Injection IP 5 mg / 1ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	17	1125	Hyoscine Butyl Bromide Injection IP 20 mg / ml 1 amp	Submitted, May be considered after submission of NCC certificate	May not be considered
	18	417	Lignocaine Hcl Injection IP 5 percentage in 2ml ampoule	Not submitted, May be considered after submission of product approval	May not be considered
	19	2330	Lignocaine Hydrochloride Injection I.P. 5 Percentage w/ v	Not submitted, May be considered after submission of product approval	May not be considered
	20	1308	Losartan Potassium Tablets IP 50 mg (film coated)	License submitted product pg no18 approval for uncoated, but not at s.no. 654 of pg no18,	May not be considered
	21	1640	Methyl Cobalamin Injection 500mcg in 1 ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	22	4036	Metronidazole ointment/Gel (1.5percentage w/w of metronidazole 20)	Submitted, May be considered after submission of NCC certificate	May not be considered
	23	527.01	Paracetamol Injection 300mg in 2ml	Submitted, May be considered after submission of NCC certificate	May not be considered
	24	2380	Phenobarbitone Injection 200mg/ml, 1ml Ampoules	Submitted, May be considered after submission of NCC certificate	May not be considered
	25	2122	Pioglitazone Tab 15mg	Submitted, May be considered after submission of NCC certificate	May not be considered
	26	607	Ranitidine Hcl Injection IP 25 mg / ml in 2ml amp	Submitted, May be considered after submission of NCC certificate	May not be considered
2	<b>ACCENT PHARMACEUTICALS DIAGNOSTICS</b>	Firm Remarks: All the required documents are in order and are satisfactory. Hence the firm is considered			
	1	1691	Aciclovir Tablets IP 400 mg		Considered
	2	1741	Baclofen Tablet IP 10mg		Considered
	3	2071	Carvedilol Tablets 3.125mg		Considered
	4	1295	Chlorpromazine Tablets IP 100 mg		Considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
	5	252	Enalapril Tablets 10mg		Considered
	6	2281	Escitalopram Tablets 5mg		Considered
	7	746	Haloperidol Tablets IP 5mg		Considered
	8	1696	Norethisterone Tablets IP 5 mg		Considered
	9	1929	Quetiapine Tab 100mg		Considered
3	<b>CADILA PHARMACEUTICALS LIMITED</b>	Firm Remarks: Firm may be considered for products at S.No. 1, 3, 4, 5, 6 & 8. Firm may also be considered for products at S.No. 2 & 7 after submission of product approval with required pack size			
	1	1622	Cefixime Tablets IP 200 mg		Considered
	2	221.02	Dexamethasone Injection IP 8 mg / 2ml	Valid product approval not enclosed (Firm enclosed product approval & pack size of 10ml instead of 2ml) May be considered after submission of valid product approval	May not be considered
	3	1215	Dicyclomine Hcl Injection IP 10mg/ml in 2ml amp		Considered
	4	252	Enalapril Tablets 10mg		Considered
	5	2369	Olmesartan Medoxomil Tablets 40mg		Considered
	6	605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg		Considered
	7	607	Ranitidine Hcl Injection IP 25 mg / ml in 2ml amp	Valid product approval not enclosed (Firm enclosed product approval & pack size of 5ml instead of 2ml) May be considered after submission of valid product approval	May not be considered
	8	2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		Considered
4	<b>CIPCO PHARMACEUTICALS</b>	Firm Remarks: Firm may be considered for products at S.No. 1 to 5.			
	1	1230	Hydrochlorothiazide Tab 25mg		Considered
	2	1308	Losartan Potassium Tablets IP 50 mg (film coated)		Considered
	3	1642	Metronidazole Tablets IP 200 mg (Film Coated )		Considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
	4	438.01	Metronidazole Tablets IP 400 mg (Film Coated )		Considered
	5	482	Norfloxacin Tablets IP 400mg		Considered
5	CIPLA LTD	Firm Remarks: Firm may be considered after submission of valid NCC of M/s Ahlcon Parenterals & valid product approvals for the products at S.No. 1, 4, 5			
	1	1691	Aciclovir Tablets IP 400 mg	Valid product approval not enclosed, Firm may be considered after submission of valid product approval	May not be considered
	2	1695	Amiodarone Hcl Tablets IP 100 mg		Considered
	3	2071	Carvedilol Tablets 3.125mg		Considered
	4	1621	Cefixime Dispersible tablet USP 100 mg	Valid product approval not enclosed, Firm may be considered after submission of valid product approval	May not be considered
	5	1622	Cefixime Tablets IP 200 mg	Valid product approval not enclosed, Firm may be considered after submission of valid product approval	May not be considered
	6	123	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml		Considered
	7	1660	Ofloxacin ophthalmic solution IP 0.3 Percentagew/v in 5ml		Considered
	8	2369	Olmesartan Medoxomil Tablets 40mg		Considered
	9	543	Propranolol Hcl Tablets IP 40 mg		Considered
	10	1930	Ramipril Tablets IP 5mg		Considered
	11	2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		Considered
6	HAB PHARMACEUTICALS & RESEARCH LIMITED	Firm Remarks: The firm not submitted valid product approvals for all items. May be considered after submission of valid product approvals for all products and also approvals for required pack size for items in S.No. 2, 3 and 5.			

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
	1	1691	Aciclovir Tablets IP 400 mg	Not submitted valid product approval copy May be considered after submission of valid product approval	May not be considered
	2	123	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml	Not submitted valid product approval along with required pack size May be considered after submission of valid product approval along with required pack size	May not be considered
	3	303	Gentamicin Eye Drops IP 0.3 Percentage w/v in 5ml	Not submitted valid product approval along with required pack size May be considered after submission product approval with required pack size	May not be considered
	4	1308	Losartan Potassium Tablets IP 50 mg (film coated)	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	5	1660	Ofloxacin ophthalmic solution IP 0.3 Percentagew/v in 5ml	Not submitted valid product approval along with required pack size May be considered after submission of valid product approval along with required pack size	May not be considered
	6	1904	Olanzapine Tablets 10mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	7	605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	8	2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	9	1325	Serrapeptidase tablets IP 10mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
7	<b>JOHNSON AND JOHNSON PRIVATE LIMITED</b>	Firm Remarks: All the required documents are in order and are satisfactory. Hence the firm is considered for S.No. 1 product			
	1	2464	Risperidone prolonged release 25 mg Suspension		Considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status	
8	<b>KONIS PHARMACEUTICALS</b>	Firm Remarks: Firm may be considered after submission of valid GMP Certificate <b>APMSIDC Remarks: Firm has to submit Revoke/Orders issued by Licensing authority</b> <b>APDGDCA Remarks: License status needs to be verified</b>				
	1	1188	Amikacin Sulphate Injection IP 100 mg in 2 ml Ampoule		Considered	
	2	123	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml		Considered	
	3	221.02	Dexamethasone Injection IP 8 mg / 2ml		Considered	
	4	2462	Diclofenac Sodium Injection Aqueous Base 75 mg/1 ml		Considered	
	5	303	Gentamicin Eye Drops IP 0.3 Percentage w/v in 5ml		Considered	
9	<b>Pontika Aerotech Limited</b>	Firm Remarks: Firm may be considered for product at s.no. 1 after submission of renewal copy of product approval & specific pack size				
	1	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage 1 plus Ab.alcohol13.1 percentage (Dettol ) in 1 liter bottle.	May be considered after submission of renewal copy of Prouduct approval & specific/required pack size	May not be considered	
10	<b>REVAT LABORATORIES PRIVATE LIMITED</b>	Firm Remarks: (1) The firm submitted required documents except for item in S.No. 5 (2) Not submitted product approval for item in S.No. 5 <b>APDGDCA Remarks: License status needs to be verified</b>				
	1	1308	Losartan Potassium Tablets IP 50 mg (film coated)		Considered	
	2	1642	Metronidazole Tablets IP 200 mg (Film Coated )		Considered	
	3	438.01	Metronidazole Tablets IP 400 mg (Film Coated )		Considered	
	4	482	Norfloxacin Tablets IP 400mg		Considered	
	5	2126	Pregabalin SR Tablet 75mg	Not submitted product approval May be considered after submission of product approval	May not be considered	
	6	2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		Considered	
	7	1325	Serrapeptidase tablets IP 10mg		Considered	

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
11	Sai Parenterals Pvt.Ltd	Firm Remarks: (1) Firm may be considered for products at S.No. 1 to 7 Firm may also be considered for products at S.No. 8 after submission of product approval & specific pack size			
	1	1188	Amikacin Sulphate Injection IP 100 mg in 2 ml Ampoule		Considered
	2	1622	Cefixime Tablets IP 200 mg		Considered
	3	1752	Cefuroxime Injection IP 250 mg vial		Considered
	4	2462	Diclofenac Sodium Injection Aqueous Base 75 mg/1 ml		Considered
	5	1640	Methyl Cobalamin Injection 500mcg in 1 ml		Considered
	6	1904	Olanzapine Tablets 10mg		Considered
	7	1903	Olanzapine Tablets 5 mg		Considered
	8	607	Ranitidine Hcl Injection IP 25 mg / ml in 2ml amp	Valid product approval enclosed but firm has not submitted for required pack size May be considered after submission of approval & specific pack size	May not be considered
12	SEEKO BIOTICS	Firm Remarks: (1) Products in S.No. 1, 3, 4, 5, 6, 7, 9, 10, 11, 12 may be considered after submission of valid GMP certificate The product in S.No. 2 and 8 may be considered after submission of valid product approval & valid GMP certificate <b>APMSIDC Remarks: Firm has to submit Revoke/Orders issued by Licensing authority</b> <b>APDGDCA Remarks: License status needs to be verified</b>			
	1	1621	Cefixime Dispersible tablet USP 100 mg		Considered
	2	1622	Cefixime Tablets IP 200 mg	Submitted not valid product approval May be considered after submission of valid product approval	May not be considered
	3	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage 1 plus Ab.alcohol13.1 percentage (Dettol ) in 1 liter bottle.		Considered
	4	265	Furosemide Tablets IP 40mg		Considered
	5	1230	Hydrochlorothiazide Tab 25mg		Considered
	6	2313	Isosorbide Dinitrate Tablets 10mg		Considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
	7	1308	Losartan Potassium Tablets IP 50 mg (film coated)		Considered
	8	1642	Metronidazole Tablets IP 200 mg (Film Coated )	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	9	438.01	Metronidazole Tablets IP 400 mg (Film Coated )		Considered
	10	482	Norfloxacin Tablets IP 400mg		Considered
	11	605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg		Considered
	12	1172	Trihexyphenidyl Hcl Tablets IP 2mg		Considered
13	<b>STRIDE ORGANICS PVT LTD</b>	Firm Remarks: All the required documents are in order and are satisfactory. Hence the firm is considered for S.No. 1, 2, 3, 5, 6, 8 But products at S.No. 4 & 7 may be considered after submission of correct product approval			
	1	1621	Cefixime Dispersible tablet USP 100 mg		Considered
	2	1622	Cefixime Tablets IP 200 mg		Considered
	3	1230	Hydrochlorothiazide Tab 25mg		Considered
	4	1308	Losartan Potassium Tablets IP 50 mg (film coated)	License not submitted the film coated specification but submitted uncoated specification at S.No. 217 of pg no:106 May be considered after submission of correct product approval	May not be considered
	5	438.01	Metronidazole Tablets IP 400 mg (Film Coated )		Considered
	6	482	Norfloxacin Tablets IP 400mg		Considered
	7	2126	Pregabalin SR Tablet 75mg	License submitted Film coated at S.No. 285 at pg no.10d, but not submitted the sustain release specification May be considered after submission of correct product approval	May not be considered
	8	605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg		Considered



S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
14	<b>TAS MED (INDIA) PRIVATE LIMITED</b>	Firm Remarks: The firm may be considered for all items after submission of valid GMP certificate.			
	1	2064	Amitriptyline Tablets IP 10mg		Considered
	2	2281	Escitalopram Tablets 5mg		Considered
	3	2292	Flunarizine Tablets 10mg		Considered
	4	746	Haloperidol Tablets IP 5mg		Considered
	5	1308	Losartan Potassium Tablets IP 50 mg (film coated)		Considered
	6	1904	Olanzapine Tablets 10mg		Considered
	7	1903	Olanzapine Tablets 5 mg		Considered
	8	2369	Olmesartan Medoxomil Tablets 40mg		Considered
	9	2122	Pioglitazone Tab 15mg		Considered
	10	2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		Considered
15	<b>THE SWASTIKPHARMACEUTICALS</b>	Firm Remarks: The firm may be considered after submission of product approval with required packsize			
	1	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage 1 plus Ab.alcohol13.1 percentage (Dettol ) in 1 liter bottle.	Submitted valid product approval but not mentioned required pack size May be considered after submission of product approval with required pack size	May not be considered
<b>Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PMon 27.02.2024 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 158-2 (General Medicines) TEC Report</b>					